

1 **Long title: When evidence is not enough: A qualitative exploration of healthcare workers'**  
2 **perspectives on expansion of two-way texting (2wT) for post- circumcision follow-up in**  
3 **South Africa**

4  
5 **Short title: Qualitative Study of Two-Way Texting for Circumcision Study in South Africa**

6  
7 Isabella Fabens,<sup>1</sup> Calsile Makhele,<sup>2</sup> Nelson Igaba,<sup>3</sup> Khumbulani Moyo,<sup>3</sup> Felex Ndebele,<sup>2</sup>  
8 Jacqueline Pienaar,<sup>2</sup> Geoffrey Setswe,<sup>2,4</sup> Caryl Feldacker<sup>1,5</sup>

- 9 1. International Training and Education Center for Health, Department of Global Health,  
10 University of Washington, Seattle, WA, United States  
11 2. Aurum Institute, Johannesburg, South Africa  
12 3. Right to Care, Pretoria, South Africa  
13 4. Department of Health Studies, University of South Africa, Pretoria, South Africa  
14 5. Department of Global Health, University of Washington, Seattle, WA USA

15  
16 Author Contributions:

17  
18 *Conceptualization:* Caryl Feldacker, Calsile Makhele

19  
20 *Formal Analysis:* Isabella Fabens, Calsile Makhele, Caryl Feldacker

21  
22 *Investigation:* Calsile Makhele

23  
24 *Methodology:* Caryl Feldacker, Geoffrey Setswe  
This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25

26 *Project administration:* Caryl Feldacker, Geoffrey Setswe

27

28 *Supervision:* Nelson Igaba, Khumbulani Moyo, Felex Ndebele, Jacqueline Pienaar, Geoffrey

29 Setswe, Caryl Feldacker

30

31 *Validation:* Calsile Makhele

32

33 *Writing – original draft:* Isabella Fabens, Caryl Feldacker

34

35 *Writing – review & editing:* Isabella Fabens, Calsile Makhele, Nelson Igaba, Felex Ndebele,

36 Jacqueline Pienaar, Geoffrey Setswe, Caryl Feldacker

37

38

39 Corresponding Author:

40 Caryl Feldacker, MPH, PhD

41 Department of Global Health, University of Washington

42 Hans Rosling Center, 3980

43 15th Ave NE Seattle, WA, 98105 United States Phone: 1 (206) 221 4970

44 Email: [cfeld@uw.edu](mailto:cfeld@uw.edu)

45

46

47 Abstract

48 As per national guidelines, in-person follow-up visits after voluntary medical male  
49 circumcision (VMMC) are required but may be unnecessary. Two-way texting (2wT) engages  
50 clients in post-operative care and triages those with complications to in-person review. 2wT-  
51 based telehealth was found to be safe, effective, and efficient. In South Africa, to understand  
52 provider perspectives on the 2wT approach and potential for expansion, 20 key informant  
53 interviews were conducted with management, clinicians, data officials and support staff  
54 involved in 2wT scale-up. Interviews were analyzed using rapid qualitative methods and  
55 informed by two implementation science frameworks: the Reach, Effectiveness, Adoption,  
56 Implementation and Maintenance (RE-AIM) framework and the Pragmatic, Robust,  
57 Implementation and Sustainability Model (PRISM). Participants submitted mixed and multi-  
58 faceted feedback, including that 2wT improves monitoring and evaluation of clients and  
59 clinical outcomes while also reducing follow-up visits. Challenges included duplicative routine  
60 and 2wT reporting systems and perceptions that 2wT increased workload. To improve the  
61 likelihood of successful 2wT scale-up in routine VMMC settings, respondents suggested:  
62 further 2wT sensitization to ensure clinician and support staff buy-in; a dedicated clinician or  
63 nurse to manage telehealth clients; improved dashboards to better visualize 2wT client data;  
64 mobilizing 2wT champions at facilities to garner support for 2wT as routine care; and,  
65 updating VMMC guidelines to support VMMC telehealth. As attendance at follow-up visits  
66 may not be as high as reported, implementing 2wT may require more effort but also brings  
67 added benefits of client verification and documented follow-up. The transition from research  
68 to routine practice is challenging, but use of RE-AIM and PRISM indicate that it is not  
69 impossible. As VMMC funding is decreasing, more effort to share the evidence base for 2wT

70 as a safe, cost-effective, high-quality approach for VMMC follow-up is needed to encourage  
71 widespread uptake and adoption.

## 72 Introduction

73 Although voluntary medical male circumcision (VMMC) is a safe procedure with few adverse  
74 events (AEs) [1-6], global VMMC guidelines still require clients to attend two post-operative  
75 follow-up visits within 14 days to ensure timely identification and treatment for AEs. This  
76 presents an undue burden for providers and clients [7, 8] creating potential barriers to  
77 continued VMMC expansion in support of HIV prevention efforts. Therefore, in 2018, the  
78 International Training and Education Center for Health (I-TECH) at the University of  
79 Washington (UW) implemented a two-way texting (2wT) approach to provide SMS-based  
80 telehealth in Zimbabwe, ensuring a safe and more efficient option for VMMC follow-up. In  
81 2021, I-TECH partnered with the Aurum Institute, the Centre for HIV-AIDS Prevention Studies  
82 (CHAPS), and Right to Care to expand on this work in South Africa, first conducting a  
83 randomized controlled trial (RCT) and then an expansion trial. Similar to Zimbabwe results [9,  
84 10], 2wT was found effective to provide safe, lower-cost, follow-up that greatly benefitted  
85 VMMC clients who approved of the approach [8, 11-13]. Previous qualitative study among  
86 healthcare workers (HCW) in both Zimbabwe [14, 15] and South Africa [13] found 2wT to be  
87 useful, acceptable, and highly usable. However, from the HCW implementation perspective,  
88 challenges were identified in duplicative VMMC reporting systems that increased workload,  
89 the need for specific 2wT personnel, and the need for improved client wound care counseling  
90 to reduce concerns that clients were unable to identify complications swiftly.

91

92 In this qualitative study on 2wT expansion potential in South Africa, our objective was to  
93 complement previous findings by focusing on new opportunities for adaptation and  
94 identifying additional potential pitfalls moving 2wT from research to routine VMMC settings

95 with routine VMMC service delivery teams. Although rigorous implementation science (IS)  
96 studies of mobile health (mHealth) interventions remain rare, we used an IS approach to help  
97 understand how, why or for whom this translation of the 2wT mHealth implementation might  
98 fail or succeed [16, 17]. As part of an expansion study of the impact of 2wT on VMMC follow-  
99 up in routine settings in South Africa, we used two complementary IS frameworks to  
100 qualitatively evaluate the 2wT approach in routine practice. We applied the RE-AIM (Reach,  
101 Effectiveness, Adoption, Implementation and Maintenance) framework alongside its  
102 complement, the Practical, Robust Implementation and Sustainability Model (PRISM), to  
103 explore factors that facilitate or curtail 2wT expansion potential [18]. While the RCT and  
104 forthcoming stepped wedge study outcomes provides strong, quantitative evidence for  
105 individual (client) *reach* and *effectiveness* of RE-AIM [18], we qualitatively explored *adoption*  
106 and *implementation* at the clinician and organizational levels to enhance assessment of 2wT  
107 impact. PRISM helps explore additional contextual factors surrounding implementation  
108 including external factors that may influence 2wT maintenance.

109  
110 We conducted 20 key informant interviews (KIIs) with HCWs, including clinicians, clerks,  
111 monitoring and evaluation (M&E) leads, and managers to gain insights into 2wT bottlenecks  
112 and suggestions for implementation improvements to inform next steps for 2wT expansion.  
113 We explored issues related to provider adoption (uptake) of 2wT, including soliciting  
114 perspectives on client, clinic, organization and structural factors that could influence  
115 successful scale-up. This participatory, 2wT user-centered approach also aimed to help  
116 identify technology gaps and features for improved patient, provider, and organizational  
117 experience using 2wT. Identifying further 2wT implementation enhancements could also help  
118 optimize the approach in South Africa and the region more broadly.

119

## 120 Methods

### 121 *Routine VMMC service delivery*

122 The US President’s Emergency Plan for AIDS Relief (PEPFAR) recommends VMMC for males  
123 ages 15 and older across 15 priority countries in Eastern and Southern Africa as a cost-  
124 effective components of comprehensive HIV prevention [19]. Post-VMMC follow-up at least  
125 once within 14 days is required [20], through PEPFAR specifically endorses 2wT for low-risk  
126 patients [19]. All VMMC care, regardless of follow-up method, is provided free in National  
127 Department of Health (NDoH) facilities in accordance with VMMC guidelines [21]. Clients are  
128 asked to return for scheduled day 2 and day 7 visits; some clinics or teams provide transport  
129 for clients unable to return for review. Sites used the standardized PEPFAR approach to  
130 assess, identify, and record the timing, type and severity of AEs [22]. For patients who miss  
131 day 2 visits, clinicians follow-up via phone call. VMMC teams are expected to report key  
132 PEPFAR outcomes: VMMC productivity by age group; AEs by severity and type; and # of  
133 VMMC clients with at least 1 follow-up visit within 14 days [20]. In addition to NDoH routine  
134 reporting forms, some implementing partners, including Right to Care, collect additional  
135 client M&E data from their clinician and clerical teams.

136

### 137 *2wT Expansion Trial*

138 We conducted a modified stepped wedge designed (SWD) study from January 30 – October  
139 19, 2023, in Ekurhuleni District (Gauteng Province) and Dr. Kenneth Kaunda District (North  
140 West Province) [23]. As 2wT rolled out, clients during intervention periods were able to opt

141 in to 2wT via Short Message Service (SMS) or choose standard of care (in-person visits).  
142 Clinicians retained discretion on 2wT enrollment; 2wT enrollment was not offered at all sites  
143 at all times. From January 30 – August 16. Between August 17 – October 19, only, WhatsApp  
144 was offered in addition to SMS as a platform for 2wT communication.

145

#### 146 *2wT Technology and Implementation*

147 The 2wT system has been described in detail previously [8, 9, 24]. In brief, the 2wT model is  
148 a hybrid mHealth system that combines automated and personalized messages between  
149 clients and a VMMC nurse on SMS or WhatsApp. Males ages 15 and above with a phone  
150 present at their VMMC appointment were eligible to enroll for the opt-in 2wT follow-up  
151 approach. On the day of VMMC, clients were educated about using the 2wT follow-up option  
152 in lieu of scheduled post-operative visits and given a pamphlet with instructions and  
153 emergency contacts. After discharge, on Days 1-3, 5, 7, 10 and 13, 2wT participants were sent  
154 automated messages in the language they chose asking them to respond about complications  
155 like bleeding, swelling, or wound opening their healing. On the other days (4, 6, 8, 9, 11 and  
156 12), they were sent educational messages. If no response was received by day 3 for minors or  
157 day 8 for adults, a nurse followed up to trace the clients and ensure healthy healing.

158

159 2wT was implemented as a hub and spoke model for the SWD study. Spokes were routine  
160 VMMC service delivery sites where non-study teams performed VMMC procedures and  
161 counseling according to NDoH standards. Spokes recruited, enrolled, and educated clients on  
162 the 2wT system and reviewed 2wT clients who needed follow-up care. The hub was a  
163 centrally located, study-specific, VMMC nurse who responded to clients, called clients who



164 did not respond, and referred clients to spoke (facilities) for follow-up care. When clients  
165 responded to the system with a concern, the “hub nurse” responded, triaged, and referred to  
166 spoke sites if needed. Clinicians from “spoke” facilities were asked to check the 2wT system  
167 in addition to other circumcision duties. Spoke clinicians could also respond to messages  
168 when necessary. Spoke site staff were responsible for filling paper forms for routine and 2wT  
169 clients.

### 170 *Conceptual model*


171 The conceptual model and qualitative approach was created using two common IS  
172 frameworks to guide successful translation of research to routine practice. RE-AIM [18, 25]  
173 was operationalized at the staff/setting levels (adoption and implementation) to guide  
174 measurement of what, where, when, and how the 2wT intervention was implemented (Figure  
175 1) [26, 27]. KIIs with 2wT managers, clinicians, M&E data specialists and support staff  
176 identified insights into how to improve the 2wT system and its implementation. Second, the  
177 study team incorporated aspects of PRISM [28] to inform actionable recommendations,  
178 including internal fit (HCW and clinical context) and external fit for context (South African  
179 VMMC policies and guidelines) [29]. The combined RE-AIM and PRISM-informed model [25]  
180 (Figure 1) shaped the interview guide, analysis, and recommendations.

181

182 *Figure 1: Adaptation of the Practical, Robust Implementation and Sustainability Model (PRISM)*

183 *Framework\* for the Stepped-Wedge Study*

184



185

186 *\*Model adapted from: Glasgow et al. (2019) [25] that expanded upon the PRISM framework*  
187 *(Feldstein & Glasgow, 2008) [28]. Constructs in yellow were explored in this study.*

188 *Data collection and analysis*

189 Key informant interviews (KIIs) were conducted from November 20, 2023, to January 19,  
190 2024. Using the conceptual model, the study team developed a semi-structured interview  
191 guide, which was pilot tested through an initial practice interview in which the participant  
192 critiqued the guide and the study team made improvements. Key informants (KIs) were  
193 recruited in person from facilities involved in the expansion trial, using maximum variation  
194 sampling to include representation from those in leadership positions, clinicians, M&E data

195 officers and demand creation officers, aiming for saturation of themes among selected  
196 respondents. A multi-lingual interviewer (author CM) conducted interviews in English;  
197 respondents also responded in IsiZulu, Sesotho or Setswana. Only the interviewer and  
198 participant were present at the time of the interview. Interviews were recorded at the  
199 participant's respective facility and took between 12 minutes and 1 hour 23 minutes, an  
200 average of 53 minutes. Interviews were transcribed and translated into English. The  
201 interviewer and a researcher from UW analyzed interviews using rapid qualitative analysis  
202 [30, 31] and a combined deductive and inductive approach. Throughout the analytic process,  
203 the broad study team was involved in categorization, thematic analysis, and interpretation of  
204 results, raising the likelihood that interview suggestions could be translated to fit  
205 improvement. The analysts wrote 2-page summaries of each interview, created a list of  
206 themes from summaries and prepared the results using a matrix to inform recommendations.  
207 Results presented in this analysis largely exclude themes that were well explored previously.

208

### 209 *Positionality*

210 The research team includes male and female individuals from UW's I-TECH, Aurum, and Right  
211 to Care. Author CM from Aurum conducted interviews; CM is a black African female. All  
212 members of the research team were also involved in 2wT implementation and familiar with  
213 the expansion trial; however, none of the authors were primarily based at a facility  
214 implementing 2wT.

### 215 *Ethics*

216 The review boards of UW (No. 00009703; CF) and the University of Witwatersrand, Human  
217 Research Ethics Committee (No. 200204; GS) approved the study protocol for the routine  
218 scale-up of 2wT as part of the step-wedge study. KII participants completed a written  
219 informed consent. No personal identifiers were included in the analyzed data.

220

221

## 222 Results

223

224 Using the conceptual model, findings are presented in three thematic groupings: 1)  
225 implementation, including factors related to adoption; 2) 2wT internal program fit factors  
226 including training and staffing of clinicians and support staff; and 3) the external fit to South  
227 African context, including VMMC policies and guidelines.

### 228 *Participant Characteristics*

229 Interviews from twenty people were included in analysis; data from one KI was excluded as  
230 they were not a direct user of the 2wT system (Table 1).

231

232 Table 1. Participant job categories

Type of Employee	Number
Management	4
Clinicians	6
M&E Data team	8
Support staff	2

<b>Total</b>	<b>20</b>
--------------	-----------

233

234

235 *Implementation*

236 *Improve 2wT as a Monitoring and Evaluation (M&E) Tool*

237 Many respondents noted advantages of 2wT for M&E. Some participants understood that  
238 2wT improved follow-up verification, reporting and planning, including that it provides a  
239 record of patient care, improves time management and increases communication among  
240 clinicians. Other participants noted that the 2wT system allows clinicians to address tasks at  
241 their own pace and document client care within the system. They added that the system also  
242 captures patient details, so information can be accessed by teams from any location. Before  
243 2wT, a KI reported that when males could not afford transportation to the VMMC clinic, they  
244 could be reviewed at their nearest clinic with data on local paper forms, resulting in gaps in  
245 client records. Participants also appreciated improved communication between clients and  
246 providers, remarking that clients could ask their providers questions at any time via SMS,  
247 filling in potential gaps in education. In addition, KIs thought that 2wT could improve AE  
248 reporting, since males in routine care seldom returned for their follow-up visits.

249

250 *“Some of them would sit and not even want to come in. If they hadn't texted via [2wT]*  
251 *we would not even know, because sometimes you would call a patient and they'll say*  
252 *no, I'm fine. And the patient is not okay. So, when it's a red flag on that side, then we*  
253 *can eventually communicate with them. So yeah, it did help a lot.” [Participant 16]*

254

255 Despite noted benefits of 2wT for M&E, many respondents noted that added burden of  
256 parallel reporting systems as clinicians are required to report all clients, including 2wT clients,  
257 on routine NDoH forms. This documentation duplication between the digital system and on  
258 paper greatly reduced enthusiasm and buy-in. One participant noted a possible solution is  
259 that 2wT could replace some of the required NDoH paper documentation.

260

261 *“I think the amount of writing whether it's [2wT] or follow up on paper, eventually*  
262 *becomes heavy on anyone. But if I was just focused on the 2-way texting, already [the*  
263 *provider] and the clients have typed something.” [Participant 21]*

264

265 *Ensure 2wT clients are well educated in wound care and AE identification*

266 Potential benefits of 2wT were muted by concerns about client safety using the telehealth  
267 approach. While some participants felt 2wT increased their ability to identify AEs, some were  
268 concerned that AEs would be missed. One participant recommended that patients first come  
269 for their 2-day check-in, and then start 2wT. Other clinicians feared that post-operative client  
270 education was not strong enough so clients would not be able to correctly identify signs of  
271 complications.

272

273 *“Because the client is not a qualified somebody, [they will] not be able to pick it up*  
274 *because the client will say there is no AE. And the hub nurse would say, ‘no there is no*  
275 *AE’. But you find that there is an infection hiding somewhere. Only a qualified*  
276 *[clinician] can actually see that something is not 100 percent.” [Participant 10]*

277

278

279 *Apply 2wT eligibility criteria consistently for appropriate client enrollment*

280 Over time, providers noted that they learned to be more selective in who they enrolled into  
281 2wT and who they required to attend in-person reviews. A few providers mentioned  
282 experiences with minors that led them to stop enrolling them or do so under more scrutiny.  
283 For example, some minors do not have a phone and use their parent or guardian's phone, so  
284 the guardian needs to be home with the client and attentive to the messages. Also, clinicians  
285 were concerned about allowing clients to enroll via WhatsApp as clients might not have a data  
286 plan, instead requiring clients to enroll using SMS which was free. Overall, the need to  
287 consider each client, individually, and match the 2wT intervention to the client was  
288 considered prudent.

289 *Enhance 2wT system functionalities*

290 Participants recommended additional 2wT system functionalities, including offering the  
291 routine texts in more languages to better include clients from neighboring countries who  
292 speak different languages. Respondents also recommended adapting the system to allow  
293 clients to send photos or submit voice notes, reducing client literacy or language barriers.  
294 Finally, a suggestion for improved notifications was to include sound alerts when new  
295 messages came in from clients, especially for those submitting potential AEs.

296 *Internal fit factors*

297 *Offer hands-on trainings and follow-up mentoring to ensure confidence in 2wT use*

298 Most participants found the 2wT trainings to be helpful, especially the practical elements in  
299 which trainers showed trainees how to use the system. One participant in a demand creation  
300 role (recruits and finds non-responsive clients for follow-up) noted they wanted to be more  
301 involved in trainings, *“I would like to have a proper training now ... even though I’m at the field  
302 ... I must be empowered” [Participant 2]*. Participants preferred 2wT-specific mentoring,  
303 including in-person check-ins or virtual support through phone or video calling.

304

305 *“We need to do some in-service training amongst ourselves, just to remind ourselves  
306 which aspects are more [important], what basis we need to touch on during the in-  
307 service training. We sometimes have weekly meetings where we sit down and talk and  
308 look at the aspects. I think those meetings can be [improved].” [Participant 8]*

309

310 *Appoint dedicated staff for 2wT as part of routine VMMC care*

311 Several participants mentioned that 2wT was easy to use, but comfort with the system  
312 increased over time. One expressed their slower uptake: *“We are also still new on this 2way  
313 texting. We are being resistant to change, but I think it will work better with time [Participant  
314 19]*. To speed expanded 2wT use at site-level, many participants recommended 2wT should  
315 have dedicated staff at facilities to reduce the perceived 2wT workload as additional to  
316 routine VMMC duties.

317

318 *“If it’s just us and there are too many clients, we suffocate and there’s nothing we can do. One  
319 day we had 21 clients. [There were only two of us] and then imagine [us] having to cut and*



320 *enroll. And then assuming that each client is five minutes, that's more than an hour. Then*  
321 *were like, okay, let's cut everyone then we will enroll after. ... And we ended up unable to enroll*  
322 *the clients unfortunately, because after 6, clients had to go home."* [Participant 8]

323

324 Moreover, respondents also thought that a dedicated staff person could help improve  
325 coordination. Monitoring clients within the 2wT system can be difficult to coordinate when  
326 in-person patients are also waiting. Learning how to balance the in-person reviews with the  
327 need to respond to 2wT clients via SMS or WhatsApp proved challenging.

328

329 *"My sense was that it was more of us being all over and not being able to properly coordinate*  
330 *that, but for example, I think at some facilities you were able to see that, at least this person*  
331 *is the one that is doing it. Then you can see some kind of stability, but as soon as that person*  
332 *is not there, then there's no one who takes over. So, there was no proper coordination of this."*  
333 [Participant 18]

334 *Identify a 2wT champion to encourage adoption of the 2wT approach*

335 While many participants requested dedicated 2wT staff, others felt that a 2wT champion was  
336 missing to drive internal clinic enthusiasm. Some considered 2wT as an external study, not a  
337 component of routine VMMC care, with one person stating that 2wT is *"still a study, so we*  
338 *don't even know if this thing works or not. But you guys are already forcing it on us."*  
339 [Participant 14]. Another participant identified that when only one person at the clinic uses  
340 2wT, its implementation stops when that person leaves. That same respondent noted that a  
341 champion was needed to promote the advantages of 2wT and encourage adoption at the  
342 clinic. *"We could not master...how we should be benefiting actually from 2-way texting*

343 *especially because of not having the person champion the 2-way texting. [We were unable] to*  
344 *properly coordinate.” [Participant 18].*

345 *External fit factors to context*

346 *Adapt VMMC guidelines to realities on the ground*

347 Participants noted that completing all required in-person reviews was challenging. In part,  
348 many clients faced transportation issues or clients attending on Day 2 would not complete  
349 additional follow-up visits. These realities, combined with the pressure to report adherence  
350 to required visits for the funder, could lead to overreporting of post-operative visit  
351 attendance. One respondent noted they felt obligated to report near 100% follow-up even if  
352 many clients were unable or chose not to return for in-person visits.

353

354 *“We would always have problems when we report to the funder, because the*  
355 *documents will not be filled. But the system will be saying 100% or 98%. If it's not*  
356 *documented, it means it's not done.” [Participant 10]*

357

358 *Allow virtual follow up option in VMMC guidelines*

359 Participants mentioned that enrolling clients in 2wT conflicts with the NDoH guidelines that  
360 require in-person visits, resulting in low support for 2wT uptake and expansion. *“In [District*  
361 *X], I know the Department of Health does not like 2wT. I don't know if it's because, according*  
362 *to the guidelines, [we] need to physically see the clients. [Participant 14]* Respondents were  
363 concerned about promoting an approach that contrasted to the in-person review  
364 requirement.

365

366 Discussion

367 Conversations with KIs including clinicians, M&E data officers, VMMC managers and support  
368 staff demonstrate the complexity of moving from research to routine practice for evidence-  
369 based mHealth innovations. Overall, interviewees reported several facilitators of expansion,  
370 including that 2wT increases timely communication between patients and providers; fills  
371 potential gaps in client education; improves follow-up verification; and strengthens reporting.  
372 However, implementation was stymied by several obstacles at both provider and  
373 organizational levels, including perceptions of increased workload, lack of site champions and  
374 lack of an enabling policy environment. With competing demands on clinicians' time and  
375 decreasing global VMMC funding, evidence-based, effective, safe, and cost-effective mHealth  
376 innovations like 2wT should be attractive at client, provider, and organizational levels.  
377 However, 2wT obstacles appear more influential than perceived benefits, reducing buy-in and  
378 momentum to scale. Application of the RE-AIM and PRISM frameworks shed light on several  
379 opportunities to energize 2wT buy-in and facilitate scaling across South Africa.

380

381 First, to create momentum for 2wT expansion, improved sensitization and dissemination  
382 efforts about 2wT benefits for clinical care are needed. During the expansion trial, the  
383 evidence of 2wT safety and efficiency benefits were not well disseminated. Without  
384 knowledge of the RCT outcomes, providers lacked confidence that 2wT could ensure quality  
385 care with referral and tracing safeguards. Moreover, 2wT awareness and education sessions  
386 for HCWs were not sufficiently prioritized, especially in light of frequent staff turnover,  
387 weakening buy-in. Additional 2wT refresher training was also needed to bolster site teams'

388 ability to provide 2wT-specific client education, counseling, and SMS-based encouragement.  
389 Although 2wT augments, not replaces, in-person visits, site teams needed more confidence  
390 to exercise their discretion: funneling low risk clients to 2wT and scheduling minors or clients  
391 with higher perceived AE risk to in-person reviews, streamlining follow-up care overall. With  
392 additional 2wT team engagement with site clinicians and HCWs about the implementation  
393 process, it is likely that greater buy-in could be secured from these critical stakeholders to  
394 improve the innovation [32].

395

396 Alongside efforts to promote 2wT benefits for clinicians and client care, more emphasis is  
397 needed to increase awareness of 2wT benefits for data quality and client M&E. Additional,  
398 targeted training for data officers and managers on real-time 2wT dashboards with complete  
399 client data could further build support for 2wT's effect on data quality, garnering more  
400 manager support for the reporting benefits. At the organization level, lack of awareness of  
401 2wT benefits for accountability, decision-making, and client verification was also evident. In  
402 this study, the hub nurse was a strong promoter of the system and drove the creation of tasks  
403 for facilities to resolve. In the future, facility teams, themselves, would need increased  
404 encouragement and supervision to complete tasks on time, trace clients and update the 2wT  
405 system. Enhanced facility staff buy-in is needed to ensure maintained 2wT implementation.  
406 To create more enthusiasm for 2wT clinical and M&E advantages, and support expansion  
407 planning, a champion from a high 2wT uptake site should be engaged in a peer-to-peer  
408 support for 2wT adoption. These champions, either hubs or spoked, could reinvigorate 2wT  
409 enthusiasm and consideration of 2wT as a locally optimized intervention [33, 34], increasing  
410 the likelihood of successful scale-up [35].

411

412 Lastly, efforts should increase focus on 2wT's benefit to provide quality follow-up with fewer  
413 in-person reviews, rather than promote the reduction in overall VMMC workload [36].  
414 Although 2wT decreases the number of in-person reviews and costs less in comparison to two  
415 post-operative visits, HCWs work more efficiently, but not fewer hours, using 2wT. Language  
416 matters: clear understanding of the workload implications of using 2wT are needed. Second,  
417 fewer in-person follow-up visits likely happen than reported, creating a potential false  
418 workload comparison between 2wT and routine care visits. Reported VMMC follow-up rates  
419 vary, with studies finding between 63-90% of VMMC clients attending at least one visit [8, 37-  
420 39]. However, over-reporting of follow-up visits may reflect fear of consequences, including  
421 job loss or other disciplinary measures [40]. Compared to actual post-operative visits, the time  
422 required to enroll, manage, and engage with 2wT clients may be higher. Assigning a dedicated  
423 2wT nurse to manage telehealth clients or reallocation of team duties to incorporate 2wT  
424 activities and oversight structures into the routine workflow merits attention. As workflow  
425 concerns may reduce innovation adoption by frontline HCWs [41], identification of a site  
426 champion becomes even more critical to support expansion potential.

427

#### 428 *Strengths and Limitations*

429 While attention was given to maintain objectivity, the research team was involved in  
430 conducting and analyzing KIIs, a bias that cannot be quantified. Members of the NDoH were  
431 not included in KIIs; future effort would benefit from their perspective. Client perspectives  
432 [23] and common constraints of electricity, network, and funding [13, 15] were previously  
433 explored and not repeated here. Although this study aimed to enhance implantation of 2wT,  
434 suggestions to improve routine VMMC service delivery were passed to VMMC teams. The

435 specific suggestions for 2wT features and functionality were shared with the technical team  
436 who could enhance the 2wT system at scale.

437

#### 438 Conclusion

439 Increased education, sensitization, and awareness is needed to move the 2wT approach from  
440 research to routine practice creating more enthusiasm for expansion. More attention on the  
441 clinical and M&E benefits could help create champions for 2wT scale-up, overcoming hurdles  
442 in consistent uptake. Adoption of several recommendations could push the balance in favor  
443 of expansion. First, augmented education to ensure that clients are prepared to self-monitor  
444 must be consistently implemented, ensuring that clients are informed and empowered to  
445 heal safely at home. Second, 2wT M&E processes must be streamlined, including fewer  
446 redundancies with the routine VMMC reporting alongside a more user-friendly dashboard.  
447 Third, there needs to be policy coverage to allow for the 2wT telehealth approach for clients  
448 who opt-in, allowing clinician discretion to recommend in-person reviews only when needed.  
449 With clear 2wT benefits for clients, clinicians, M&E data officers and VMMC managers, more  
450 engagement of these key stakeholders could overcome identified hurdles to 2wT expansion,  
451 creating momentum to scale.

452

#### 453 References

454

- 455 1. Titus, M.J. and J. Moodley, *Male circumcision as a public health measure for the*  
456 *prevention of HIV transmission*. Southern African Journal of Epidemiology and  
457 Infection, 2011. **26**(4): p. 262-265.

- 458 2. Bershteyn, A., et al., *Understanding the Evolving Role of Voluntary Medical Male*  
459 *Circumcision as a Public Health Strategy in Eastern and Southern Africa: Opportunities*  
460 *and Challenges*. *Curr HIV/AIDS Rep*, 2022. **19**(6): p. 526-536.
- 461 3. Hellar, A., et al., *Adverse events in a large-scale VMMC programme in Tanzania:*  
462 *findings from a case series analysis*. *J Int AIDS Soc*, 2019. **22**(7): p. e25369.
- 463 4. Muchiri, E., et al., *Description of adverse events among adult men following voluntary*  
464 *medical male circumcision: Findings from a circumcision programme in two provinces*  
465 *of South Africa*. *PLoS One*, 2021. **16**(8): p. e0253960.
- 466 5. O'Bryan, G., et al., *Adverse event profile and associated factors following surgical*  
467 *voluntary medical male circumcision in two regions of Namibia, 2015-2018*. *PLoS One*,  
468 2021. **16**(10): p. e0258611.
- 469 6. Lucas, T., et al., *Consolidated Overview of Notifiable Adverse Events in the US*  
470 *President's Emergency Plan for AIDS Relief's Voluntary Medical Male Circumcision*  
471 *Program Through 2020*. *Current HIV/AIDS Reports*, 2022: p. 1-8.
- 472 7. Abunah, B., et al., *Motivators and barriers to uptake of post-operative voluntary*  
473 *medical male circumcision follow-up in Yala division, Siaya County, Kenya*. *The Pan*  
474 *African medical journal*, 2016. **25**(Suppl 2): p. 7-7.
- 475 8. Feldacker, C., et al., *Expanding the Evidence on the Safety and Efficiency of 2-Way Text*  
476 *Messaging–Based Telehealth for Voluntary Medical Male Circumcision Follow-up*  
477 *Compared With In-Person Reviews: Randomized Controlled Trial in Rural and Urban*  
478 *South Africa*. *Journal of Medical Internet Research*, 2023. **25**: p. e42111.
- 479 9. Feldacker, C., et al., *Reducing Provider Workload While Preserving Patient Safety: A*  
480 *Randomized Control Trial Using 2-Way Texting for Postoperative Follow-up in*

- 481            *Zimbabwe's Voluntary Medical Male Circumcision Program*. JAIDS Journal of Acquired  
482            Immune Deficiency Syndromes, 2020. **83**(1): p. 16-23.
- 483    10.    Babigumira, J.B., et al., *Cost-effectiveness analysis of two-way texting for post-*  
484            *operative follow-up in Zimbabwe's voluntary medical male circumcision program*. PLoS  
485            One, 2020. **15**(9): p. e0239915.
- 486    11.    Su, Y., et al., *Cost savings in male circumcision post-operative care using two-way text-*  
487            *based follow-up in rural and urban South Africa*. PLOS ONE, 2023. **18**(11): p. e0294449.
- 488    12.    Pienaar, J., et al., *'I understood the texting process well'. Participant perspectives on*  
489            *usability and acceptability of SMS-based telehealth follow-up after voluntary medical*  
490            *male circumcision in South Africa*. DIGITAL HEALTH, 2023. **9**: p. 20552076231194924.
- 491    13.    Day, S., et al., *Centering Frontline Health Care Workers in Digital Innovation Design to*  
492            *Inform the Optimization of an App for Improved Male Circumcision Follow-up in South*  
493            *Africa: Qualitative Usability Study*. JMIR formative research, 2023. **7**.
- 494    14.    Feldacker, C., et al., *Usability and acceptability of a two-way texting intervention for*  
495            *post-operative follow-up for voluntary medical male circumcision in Zimbabwe*. PLoS  
496            One, 2020. **15**(6): p. e0233234.
- 497    15.    Elkins, C., et al., *"Endless opportunities": A qualitative exploration of facilitators and*  
498            *barriers to scale-up of two-way texting follow-up after voluntary medical male*  
499            *circumcision in Zimbabwe*. PloS one, 2024. **19**(5): p. e0296570-e0296570.
- 500    16.    Westgard, C. and W.O. Fleming, *The Use of Implementation Science Tools to Design,*  
501            *Implement, and Monitor a Community-Based mHealth Intervention for Child Health in*  
502            *the Amazon*. Frontiers in public health, 2020. **8**.
- 503    17.    Packel, L., et al., *Preparing a financial incentive program to improve retention in HIV*  
504            *care and viral suppression for scale: using an implementation science framework to*



- 505            *evaluate an mHealth system in Tanzania*. Implementation science communications,  
506            2021. **2**(1).
- 507    18.    Glasgow, R.E., T.M. Vogt, and S.M. Boles, *Evaluating the public health impact of health*  
508            *promotion interventions: the RE-AIM framework*. American Journal of Public Health,  
509            1999. **89**(9): p. 1322-1327.
- 510    19.    *FY 2024 Technical Considerations*, D.o. State, Editor. 2023, U.S. President's Emergency  
511            Plan for AIDS Relief.
- 512    20.    *Monitoring, Evaluation and Reporting Indicator Reference Guide, MER 2.0*. 2022, U.S.  
513            President's Emergency Plan for AIDS Relief.
- 514    21.    *South African National Guidelines for Medical Male Circumcision*. 2016, Department  
515            of Health of the Republic of South Africa.
- 516    22.    Population Services International, C.o.S.o.E.C.a.S.A.U.S.C.f.D.C.a.P., *Adverse Event*  
517            *Action Guide for Voluntary Medical Male Circumcision by Surgery or Device*. 2020.
- 518    23.    Fabens, I.N., et al., *Messaging platform choice: An exploration of WhatsApp versus*  
519            *SMS for two-way, text-based follow-up after voluntary medical male circumcision in*  
520            *South Africa*. 2024, JMIR Formative Research.
- 521    24.    Marongwe, P., et al., *Transitioning a digital health innovation from research to routine*  
522            *practice: Two-way texting for male circumcision follow-up in Zimbabwe*. PLOS Digit  
523            Health, 2022. **1**(6): p. e0000066.
- 524    25.    Glasgow, R.E., et al., *RE-AIM Planning and Evaluation Framework: Adapting to New*  
525            *Science and Practice With a 20-Year Review*. Front Public Health, 2019. **7**(64): p. 64.
- 526    26.    D'Lima, D., T. Soukup, and L. Hull, *Evaluating the Application of the RE-AIM Planning*  
527            *and Evaluation Framework: An Updated Systematic Review and Exploration of*  
528            *Pragmatic Application*. Front Public Health, 2021. **9**: p. 755738.

- 529 27. Holtrop, J.S., B.A. Rabin, and R.E. Glasgow, *Qualitative approaches to use of the RE-*  
530 *AIM framework: rationale and methods*. BMC health services research, 2018. **18**(1): p.  
531 177-177.
- 532 28. Feldstein, A.C. and R.E. Glasgow, *A practical, robust implementation and sustainability*  
533 *model (PRISM) for integrating research findings into practice*. The joint commission  
534 journal on quality and patient safety, 2008. **34**(4): p. 228-243.
- 535 29. Rabin, B.A., et al., *A citation analysis and scoping systematic review of the*  
536 *operationalization of the Practical, Robust Implementation and Sustainability Model*  
537 *(PRISM)*. Implementation science : IS, 2022. **17**(1): p. 1-62.
- 538 30. Hamilton, A. *Qualitative Methods in Rapid Turn-Around Health Services Research*. in  
539 *VA HSR&D National Cyberseminar Series: Spotlight on Women's Health*. 2013. Online.
- 540 31. Hamilton, A.B. and E.P. Finley, *Qualitative methods in implementation research: An*  
541 *introduction*. Psychiatry Res, 2019. **280**: p. 112516.
- 542 32. Marcolino, M.S., et al., *The Impact of mHealth Interventions: Systematic Review of*  
543 *Systematic Reviews*. JMIR Mhealth Uhealth, 2018. **6**(1): p. e23.
- 544 33. Pettersen, S., H. Eide, and A. Berg, *The role of champions in the implementation of*  
545 *technology in healthcare services: a systematic mixed studies review*. BMC Health  
546 Services Research, 2024. **24**(1).
- 547 34. Swartz, A., et al., *Multiple pathways to scaling up and sustainability: an exploration of*  
548 *digital health solutions in South Africa*. Global Health, 2021. **17**(1): p. 77.
- 549 35. Lampariello, R. and S. Ancellin-Panzani, *Mastering stakeholders' engagement to reach*  
550 *national scale, sustainability and wide adoption of digital health initiatives: lessons*  
551 *learnt from Burkina Faso*. Fam Med Community Health, 2021. **9**(3): p. e000959.

- 552 36. Opoku, D., V. Stephani, and W. Quentin, *A realist review of mobile phone-based health*  
553 *interventions for non-communicable disease management in sub-Saharan Africa*. BMC  
554 *Medicine*, 2024. **15**(1).
- 555 37. Odeny, T.A., et al., *Text messaging for maternal and infant retention in prevention of*  
556 *mother-to-child HIV transmission services: A pragmatic stepped-wedge cluster-*  
557 *randomized trial in Kenya*. PLoS Med, 2019. **16**(10): p. e1002924.
- 558 38. Lissouba, P., et al., *A model for the roll-out of comprehensive adult male circumcision*  
559 *services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo*  
560 *Pele Project*. PLoS Med, 2010. **7**(7): p. e1000309.
- 561 39. Mutanekelwa, I., et al., *Prevalence and correlates of voluntary medical male*  
562 *circumcision adverse events among adult males in the Copperbelt Province of Zambia:*  
563 *A cross-sectional study*. Plos one, 2021. **16**(9): p. e0256955.
- 564 40. Feldacker, C., et al., *Balancing competing priorities: Quantity versus quality within a*  
565 *routine, voluntary medical male circumcision program operating at scale in Zimbabwe*.  
566 *Plos one*, 2020. **15**(10): p. e0240425.
- 567 41. Zakerabasali, S., et al., *Mobile Health Technology and Healthcare Providers: Systemic*  
568 *Barriers to Adoption*. Healthcare informatics research, 2021. **27**(4): p. 267-278.

569

570 Appendix

571 *Appendix 1: Consent to Participate in KII*

572

573 **PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT FORMS FOR HEALTHCARE**

574 **WORKERS STEP WEDGE**

575

576 **Main study:** Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-up and

577 Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in

578 Republic of South Africa

579 **Scale-Up:** Implementation of 2wT in Routine Practice with the Goal of Improving 2wT-based

580 Follow-up Within the VMMC program in South Africa (**2WT-2-Scale**)

581

582 **HREC REFERENCE NO: 200204**

583 **PROTOCOL NO: AUR2-8-270 2WT**

584

585 **2WT STUDY**

586

587 Principal Investigators:

588 Caryl Feldacker, PhD, MPH, University of Washington, Seattle, WA, USA

589 Geoffrey Setswe DrPH, MPH, The Aurum Institute, Johannesburg

590

591 **Funding Source and/or Sponsor:**

592 National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA. PI Name:  
593 Caryl Feldacker & Geoffrey Setswe: Application ID: 1 R01 NR019229-01A1. 1-866-504-9552  
594 (tty: 301-451-5939) or [commons@od.nih.gov](mailto:commons@od.nih.gov).)

595

596 **Study Contact telephone numbers:**

Name	Position	Phone number
<b>24 Hour Urgent Assistance</b>		
Felex Ndebele	Project Manager	078 149 0446

597

598 Good day, my name is \_\_\_\_\_ (INSERT NAME), I am a  
599 \_\_\_\_\_ (INSERT DESIGNATION) at The Aurum Institute. I would like to  
600 invite you to consider participating in an evaluation, entitled “Expanding and Scaling Two-way  
601 Texting to Reduce Unnecessary Follow-up and Improve Adverse Event Identification Among  
602 Voluntary Medical Male Circumcision Clients in Republic of South” Africa.

603

604 **What you should know about this evaluation:**

- 605
- 606 • We give you this consent so that you may read about the purpose, risks, and benefits of this evaluation.
  - 607 • The main goal of this evaluation is to help VMMC clients in Ekurhuleni, Dr Kenneth Kaunda, and Dr Ruth Semotsi Mompoti districts.
  - 609 • We cannot promise that this evaluation will benefit you.
  - 610 • We want to document your opinions about and satisfaction with, the 2-way texting  
611 (2WT texting) follow-up method

- 612       • You have the right to refuse to take part or agree to take part now and change your  
613       mind later.
- 614       • Please review this consent form carefully. Ask any questions before you make a  
615       decision.
- 616       • Your participation is voluntary.

617

## 618 PURPOSE

619 You are being asked to be part of an evaluation to assess the implementation of text-based  
620 follow-up after circumcision. What we learn from this evaluation will help the National  
621 Department of Health (NDOH) decide if and how to scale two-way text-based follow-up for  
622 VMMC.

623

624 Two-way texting will be implemented for approximately 800 men in all participating districts.  
625 Then, we will include up to 20 clinicians at evaluation sites, like yourself, who will also be  
626 asked questions about this evaluation and their thoughts on text-based follow-up. As a  
627 clinician, you will be asked questions such as what you know and think about the texting  
628 method.

629

630 You were asked to consider being part of this evaluation because the information you provide in  
631 this evaluation, including how satisfied you are with the texting intervention, your experience  
632 with taking care of these men via SMS, and any suggestions you have to improve the texting may  
633 improve the intervention in the future.

634

## 635 PROCEDURES AND DURATION

636 If you decide to participate the following procedures will happen: We will seek to meet you  
637 in a private place and seek informed consent from you. If you consent, you will go to a private  
638 space within the clinic, and we will solicit your opinions and experiences regarding deploying  
639 2WT. We will ask you questions like, “What were the challenges of the texting system?” The  
640 interview will take approximately 30 minutes. With your consent, the interview will be  
641 recorded.

642

### 643 **RISKS AND DISCOMFORTS**

644 Taking part in the evaluation may cause some psychological discomfort because you will be  
645 asked to provide your opinions regarding text-based follow-up after surgical circumcision.

646

### 647 **BENEFITS and COMPENSATION**

648 We cannot promise that you will receive any benefits from this evaluation. The study will  
649 help the National Department of Health (NDOH) to make male circumcision SMS follow-up  
650 stronger and, potentially, more widely available. No compensation will be offered.

651

### 652 **CONFIDENTIALITY**

653 The information you give us will be kept private (in secret). All information we collected during  
654 interviews will be locked away or kept on protected computers. No one outside of the  
655 evaluation partner will know the results of the SMS input session or your interview. Any  
656 information that could be used to identify you will be shared only with your permission and  
657 will not be used in any reports from this evaluation. The recordings will be transcribed without  
658 identifiers. The voice recordings of the interviews will be destroyed one year after the activity  
659 ends. However, the link between your identifier and the transcripts will be destroyed after

660 the records retention period required by the Aurum Institute and the University of  
661 Washington in accordance with the law. These records will be kept locked in a separate file  
662 cabinet that only evaluation staff can enter.

663 The Aurum Institute, Wits HREC, US Government, or University of Washington staff  
664 sometimes review studies such as this one to make sure they are being done safely and  
665 legally. If a review of this evaluation takes place, your records may be examined. The  
666 reviewers will protect your privacy. The evaluation records will not be used to put you at legal  
667 risk of harm. A description of this clinical trial will be available on  
668 <http://www.clinicaltrials.gov>, as required by U.S. Law. This Web site will not include  
669 information that can identify you. At most, the Web site will include a summary of the results.  
670 You can search this Web site at any time.

671 We have a Certificate of Confidentiality from the United States from the National Institutes  
672 of Health. These protections only apply to data held in the United States. This helps us protect  
673 your privacy. The certificate means that we do not have to give out information, documents,  
674 or samples that could identify you even if we are asked to by a court of law in the United  
675 States. We will use the Certificate to resist any demands for identifying information.

676 We can't use the Certificate to withhold your research information if you give your written  
677 consent to give it to an insurer, employer, or other person. Also, you or a member of your  
678 family can share information about yourself or your part in this research if you wish.

679 There are some limits to this protection. We will voluntarily provide the information to:

- 680 • a member of the United States government who needs it in order to audit or evaluate  
681 the research.



- 682 • individuals at the institution(s) conducting the research, the funding agency, and other  
683 groups involved in the research, if they need the information to make sure the  
684 research is being done correctly.
- 685 • individuals who want to conduct secondary research if allowed by federal regulations  
686 and according to your consent for future research use as described in this form.
- 687 • to relevant authorities as required by other Federal, State, or local laws.

688

689 The Certificate expires when the NIH funding for this evaluation ends. Currently, this is 31  
690 March 2025. Any data collected after expiration is not protected as described above. Data  
691 collected prior to expiration will continue to be protected

692

#### 693 **ETHICAL APPROVAL:**

- 694 • This clinical evaluation protocol has been submitted to the University of the Witwatersrand,  
695 Human Research Ethics Committee (HREC) and written approval has been granted by that  
696 committee.
- 697 • The evaluation has been structured in accordance with the Declaration of Helsinki (last  
698 updated: October 2013), which deals with the recommendations guiding doctors in  
699 biomedical research involving human participants. A copy may be obtained from me should  
700 you wish to review it.

#### 701 **FUTURE USE**

702 The information that we obtain from you for this evaluation might be used for future studies.  
703 We may remove anything that might identify you from the information and specimens. If we  
704 do so, that information may then be used for future research studies or given to another  
705 investigator without getting additional permission from you. It is also possible that in the

706 future we may want to use or share evaluation information that might identify you. If we do,  
707 a review board will decide whether or not we need to get additional permission from you.

708

### 709 **VOLUNTARY PARTICIPATION**

710 It is up to you whether you want to be part of this evaluation. Your alternative is to not  
711 participate in the evaluation. If you decide to be in it, you may stop at any time. These  
712 decisions will not affect your employment or future relationship with the NDOH or its  
713 partners. If you decide to leave the evaluation, we will ask you for information about why  
714 you are choosing to leave. It is up to you whether to answer these questions.

### 715 What if you have questions about this evaluation?

716 You have the right to ask and receive answers to questions about this research. If you have  
717 questions, complaints, or concerns, contact the researchers listed below:

718 ***Prof Geoffrey Setswe at 072 025 9875 or Jacqui Pienaar at 082 965 5098***

719

### 720 **OFFER TO ANSWER QUESTIONS**

721 Before you sign this form, please ask any questions on any aspect of this evaluation that is  
722 unclear to you. You may take as much time as necessary to think it over.

723

724

725 **AUTHORISATION**

726 I am making a decision about whether or not to participate in this evaluation. My signature  
727 indicates that I have read and understood the information provided above, have had all my  
728 questions answered, and I have decided to participate.

729  
730 The date I sign the document to enrol in this evaluation, that is, today's date, MUST fall  
731 between the dates indicated on the approval stamp affixed to each page. These dates  
732 indicate that this form is valid when I enrol in the evaluation but do not reflect how long I may  
733 participate in the evaluation.

734  
735 \_\_\_\_\_  
736 Name of Research Participant (please print) Date

737  
738 \_\_\_\_\_  
739 Signature of Participant Time in 24:00

740 format  
741  
742

743  
744  
745 \_\_\_\_\_

746 Names of Study Staff Signature of Study Staff

747 Obtaining Consent

748

749	_____	_____	_____
750	Name of Witness	Signature of witness	Time in 24:00 format
751			



776 *Appendix 2: Key Informant Interview Guide to assess acceptability of 2WT among HCWs using*  
777 *CFIR framework*

778 Adapted from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248861/>

779

780 FIRST: Interviewer MUST verify that informed consent is signed by the interviewee

781 1. Verification of informed consent? CIRCLE ONE: YES NO

782

783 General introduction:

784

785 Hello, my name is \_\_\_\_\_. Thank you for agreeing to talk to me today as  
786 part of ongoing VMMC quality improvement efforts. This interview is about your experiences  
787 whilst using the two-way-texting follow-up method that your organisation has been  
788 implementing. We will explore and cover more of your thoughts, opinions, and suggestions  
789 about the texting study that you recently helped implement to inform improvements as we  
790 considering scaling up the follow-up approach. Thank you for agreeing to participate in this  
791 interview, this should take about 45 minutes of your time. I will be asking you some questions  
792 which you are free to answer in any way you wish. You may also choose not to answer any  
793 question. I encourage you to feel free to say anything concerning the topic of discussion. If a  
794 question is unclear to you, you can ask me to explain it. Your participation is voluntary and  
795 confidential. Whatever you tell me will be treated with utmost confidentiality. The  
796 information will only be used for the purposes of this program evaluation.

797 Please allow me to record our discussion so that I don't miss anything. Your voice will not be  
798 heard by anyone other than our study team. Your name will not be recorded and will not

799 appear on the transcription or any publication. The recording will be destroyed after we have  
800 prepared our transcripts.

801 Is it okay if I tape-record our discussion? YES NO [IF NO, STOP]

802

803 **SECTION A: For all interviewees**

804 1. To get started, I'd like to learn about your involvement with 2wT. Tell me about your  
805 role in the implementation . [**Characteristics of Individuals**]

806 **Probe:** for all roles (site (enrolment, messaging, reviews, M&E, hub, M&E,  
807 management, oversight, reporting, etc.)

808

809 **SECTION B: Only for site/hub/implementation**

810

811 2. Tell me about the initial 2wT training you received. [**Inner Setting**]

812 a. What training materials were used to train you?

813 **Probe/show examples:** [be specific: did they use, like, dislike, not used]:  
814 posters, flip chart, pamphlets, user guide, (toolkit of client education), HCW  
815 cheat sheets, and short videos.

816 b. Which one was more useful to you?

817 c. What were the most useful aspects of your training?

818 **Probe:** (PowerPoint slides training, educational materials, support phone calls)

819 d. Tell me about refresher training sessions or on-site mentoring/support you  
820 received AFTER the program started?

821 • How was mentoring or support provided?

822 **Probe:** phone, WhatsApp, Zoom? In-person? Videos?

823 e. How can we improve the training?

824 **Probe:** Initial AND ongoing mentoring/support?

825 3. Now, let's talk about the implementation of the 2wT approach – you may not know all  
826 aspects, but let's talk about your experiences. From your perspective, walk me briefly  
827 through the process from client education to enrolment to interaction over 14 days to  
828 reporting. At each stage, tell me what worked well and what did not. **[Intervention**  
829 **Characteristics]**

830 a. Tell me about client sensitization on 2wT BEFORE a client is cut?

831 [How do you introduce 2wT?]

832 • Tell me about post-operative counseling? Overall, how can we  
833 improve client education?

834

835 b. How about with enrolment? What works well? What does not?

836 • How long does the enrollment confirmation take?

837 • Are there differences in SMS vs. WhatsApp?

838 c. Regarding the Daily 2wT messaging, what worked well and what did not?

839 • Following up on Potential AE reports

840 • Communicating with clients

841 d. Regarding the Task completion, what worked well and what did not? In your  
842 opinion, how easy or difficult is it to complete tasks?

843 • For referrals to care

844 • For tracing



845 e. Regarding reporting and completion of the paper follow-up (review) forms,  
846 what works well and what does not? In your opinion, how easy or difficult is it  
847 to complete paper follow-up forms using information from the system?

848

849 How can we smoothen the challenges you experienced with paper and the 2wT  
850 interface? Then how can we smoothen that?

851 **SECTION C: For all interviewees**

852

853 4. Let's talk about the effect of 2wT for VMMC at your clinic (your organization).

854 From your perspective as a HCW, **how does 2wT impact the quality of client follow-**  
855 **up?**

856 • How does 2wT help find AEs?

857 a. What is the impact of 2wT follow-up on demand creation? For HCWs, let's talk  
858 about the impact of 2wT on your follow-up workload. How did 2wT impact  
859 your follow-up workload? **[Process]**

860 **Probe:** How could we further improve 2wT to reduce workload?

861 b. How could we improve 2wT for HCWs?

862

863 5. Tell me about how the hub nurse works with the site teams [Explain: Hub is the first  
864 line of nurse messaging and referral] **[Process of Implementation]**

865 • Would you prefer the Hub nurse to be resident in your clinic or to be in a  
866 central location (one hub-to many spokes)? Why?

867

868 6. Let's talk about scaling up. We'd like to learn about how 2wT could help more clients  
869 across more VMMC sites, in both routine and the busy season or campaign period.

870 a. How many 2wT clients do you think your clinic can manage at a time?

871 b. Is this with a central hub or clinic-centred hub?

872 c. What influences whether this number goes up or down?

873 d. How could we improve 2wT for clients?

874 e. How could we improve 2wT for nurses?

875 f. How could we improve 2wT for data management?

876

877 7. Let's talk about next steps.

878

879 a. How can we make 2wT more user-friendly for workers?

880 b. How can we make it more user-friendly?

881 c. What new features or functions would you like to see in 2wT for MC?

882 d. What are influential individuals like your immediate managers (for RtC staff)

883 or your contractor (for GPs) saying about 2wT for VMMC? **[Process of**

884 **Implementation**

885 e. Where else would you like to see 2wT used

886 **Probe:** Other healthcare contexts, locations, health areas?

887

888 8. Which opportunities do you think 2wT can bring to VMMC?

889 9. What are your concerns or threats you think the implementation of 2wT can bring to  
890 VMMC?

891 10. Before we end, do you have anything else to add for the 2wT team to improve the  
892 implementation of VMMC/2wT services?

893

894

895

896

897

898